Revenue Performance:
In Q4 2024, ResMed achieved total revenue of $1.22 billion, an increase of 9.01% year-over-year and 2.19% quarter-over-quarter. The gross profit stood at $704 million, translating to a gross profit margin of 57.58%.
Profitability Metrics:
Operating income increased to $381 million, showing a year-over-year growth of 38.49%, while net income reached $292 million, marking a robust net income margin of 23.89%. Noteworthy is the EPS growth of 27.56% year-over-year, driven by both top-line growth and operational efficiency improvements.
Balance Sheet Health:
ResMed's total assets amounted to $6.87 billion, with total liabilities of $2.01 billion, yielding a debt-to-equity ratio of 0.180, indicative of a solid capital structure. The current ratio of 2.59 suggests sufficient liquidity to cover short-term obligations.
Cash Flow Management:
Net cash provided by operating activities was strong at $440 million, supporting a free cash flow of $414 million. The company’s capacity to generate cash demonstrates positive cash management, which is crucial for funding future growth and sustaining dividend payments.